Locations
Amsterdam, Netherlands · Amsterdam-Noord, Amsterdam, Netherlands
industry
Biotechnology · DeepTech · Health
Size
51-200 employees
Stage
Series B
founded in
2020
Leyden Labs is focused on developing innovative nasal sprays that deliver antibodies to the nasal mucosa, providing immediate antiviral protection against respiratory viruses. Their lead product, Pan Flu™, is designed to stop infections at the initial point of entry, preventing onward transmission and offering broad protection against existing and emerging viral strains. The company leverages a strong scientific foundation and partnerships with leading formulation and device companies to optimize mucosal delivery. With a mission to prepare society for future pandemics, Leyden Labs is positioned as a pioneer in preventative medicine, aiming to empower individuals with self-administrable solutions for viral protection.
Something looks off?On-site & Remote